Pharmacological treatment of women with heart failure (HF) in Scotland, April 1999–March 2000
| Treatment | Age group (years) | ||||||
|---|---|---|---|---|---|---|---|
| 45–64 | 65–74 | 75–84 | >85 | <75 | ⩾75 | All ages | |
| Number | 56 | 116 | 227 | 166 | 176 | 393 | 569 |
| Furosemide | 30 | 66 | 124 | 97 | 97 | 221 | 318 |
| (53.6%) | (56.9%) | (54.6%) | (58.4%) | (55.1%) | (56.2%) | (55.9%) | |
| Any diuretic | 42 | 95 | 190 | 132 | 138 | 322 | 460 |
| (75.0%) | (81.9%) | (83.7%) | (79.5%) | (78.4%) | (81.9%) | (80.8%) | |
| ACE inhibitor | 24 | 53 | 76 | 41 | 77 | 117 | 194 |
| (42.9%) | (45.7%) | (33.5%) | (24.7%) | (43.8%) | (29.8%) | (34.1%) | |
| ARB | 5 | 5 | 14 | 6 | 10 | 20 | 30 |
| (8.9%) | (4.3%) | (6.2%) | (3.6%) | (5.7%) | (5.1%) | (5.3%) | |
| β Blocker | 14 | 27 | 51 | 22 | 41 | 73 | 114 |
| (25.0%) | (23.3%) | (22.5%) | (13.3%) | (23.3%) | (18.6%) | (20.0%) | |
| Spironolactone | 3 | 10 | 13 | 12 | 13 | 25 | 38 |
| (5.4%) | (8.6%) | (5.7%) | (7.2%) | (7.4%) | (6.4%) | (6.7%) | |
| Digoxin | 6 | 18 | 43 | 35 | 25 | 78 | 103 |
| (10.7%) | (15.5%) | (18.9%) | (21.1%) | (14.2%) | (19.8%) | (18.1%) | |
| Any HF treatment | 49 | 102 | 206 | 139 | 153 | 345 | 498 |
| (87.5%) | (87.9%) | (90.7%) | (83.7%) | (86.9%) | (87.8%) | (87.5%) | |